As shown in Figure 9H, gardenoside acted as a DPP4 inhibitor to reduce the activity of DPP4 in mice of the NAFLD model, and a similar observation was also made in the si-CTCF treatment group. Here, CTCF is linked to metabolic dysfunction-associated steatotic liver disease.